The present invention has an object to provide a skin anti-aging agent, an agent for regulating expression of anti-aging related gene, and a cosmetic product comprising the anti-aging agent or the agent for regulating expression of anti-aging related gene which are very safe and can be used reliably for a long term. The skin anti-aging agent, the agent for regulating expression of anti-aging related gene, and the cosmetic product comprising the anti-aging agent or the agent for regulating expression of anti-aging related gene of the present invention comprise a special low molecular DNA and a soybean extract, preferably a soybean sprout extract, as active ingredients. These active ingredients have activating actions on the function of the dermal fibroblast and are hence expected to prevent or improve the skin aging such as the reduction of skin firmness and elasticity, wrinkles and sagging.

The present invention has an object to provide a skin anti-aging agent, an agent for regulating expression of anti-aging related gene, and a cosmetic product comprising the anti-aging agent or the agent for regulating expression of anti-aging related gene which are very safe and can be used reliably for a long term. The skin anti-aging agent, the agent for regulating expression of anti-aging related gene, and the cosmetic product comprising the anti-aging agent or the agent for regulating expression of anti-aging related gene of the present invention comprise a special low molecular DNA and a soybean extract, preferably a soybean sprout extract, as active ingredients. These active ingredients have activating actions on the function of the dermal fibroblast and are hence expected to prevent or improve the skin aging such as the reduction of skin firmness and elasticity, wrinkles and sagging.

The present disclosure relates to stable cosmetic compositions that include high levels of free glycolic acid. The cosmetic compositions typically include: glycolic acid and/or a salt thereof; at least one non-silicone fatty compound; at least one emulsifier; at least one water-soluble solvent; at least one silicone; and water. The cosmetic compositions are in the form of an emulsion, in particular, a water-in-oil emulsion, and typically have a low pH of below 7. Also, the cosmetic compositions have high amount of free glycolic acid, for example, at least 6 wt. % of free glycolic acid, based on the total weight of the cosmetic composition. The cosmetic compositions are particularly useful for improving the appearance of skin. Accordingly, the instant disclosure relates to methods of treating skin, for example, improving the appearance of skin using the cosmetic compositions.

The present disclosure relates to stable cosmetic compositions that include high levels of free glycolic acid. The cosmetic compositions typically include: glycolic acid and/or a salt thereof; at least one non-silicone fatty compound; at least one emulsifier; at least one water-soluble solvent; at least one silicone; and water. The cosmetic compositions are in the form of an emulsion, in particular, a water-in-oil emulsion, and typically have a low pH of below 7. Also, the cosmetic compositions have high amount of free glycolic acid, for example, at least 6 wt. % of free glycolic acid, based on the total weight of the cosmetic composition. The cosmetic compositions are particularly useful for improving the appearance of skin. Accordingly, the instant disclosure relates to methods of treating skin, for example, improving the appearance of skin using the cosmetic compositions.

The present disclosure describes novel peptides, including peptides that inhibit the proteolytic activity of insulin-de-grading enzyme (IDE). Also described are cosmetic and pharmaceutical formulations including these peptides, as well as a treatment method aimed at improving the appearance and/or texture of skin and/or promoting wound healing and a method for treating diabetes. The disclosed peptides and formulations are particularly useful for addressing the problem of impaired wound healing in diabetes.

The present disclosure describes novel peptides, including peptides that inhibit the proteolytic activity of insulin-de-grading enzyme (IDE). Also described are cosmetic and pharmaceutical formulations including these peptides, as well as a treatment method aimed at improving the appearance and/or texture of skin and/or promoting wound healing and a method for treating diabetes. The disclosed peptides and formulations are particularly useful for addressing the problem of impaired wound healing in diabetes.

Heptahydroxyflavan or a salt, isomer, hydrate or solvate thereof, which is an active ingredient of the present disclosure, can enhance skin elasticity and improve skin wrinkles by inhibiting the activity of MMP-1. In addition, the heptahydroxyflavan or a salt, isomer, hydrate or solvate thereof, which is an active ingredient of the present disclosure, can be used in various compositions such as cosmetics, health functional foods, etc. because it is safe with no cytotoxicity.

Heptahydroxyflavan or a salt, isomer, hydrate or solvate thereof, which is an active ingredient of the present disclosure, can enhance skin elasticity and improve skin wrinkles by inhibiting the activity of MMP-1. In addition, the heptahydroxyflavan or a salt, isomer, hydrate or solvate thereof, which is an active ingredient of the present disclosure, can be used in various compositions such as cosmetics, health functional foods, etc. because it is safe with no cytotoxicity.

Compositions are provided that contain biologically active components of amniotic fluid including growth factors and other proteins, carbohydrates, lipids, and metabolites. The compositions containing biologically active components of amniotic fluid can be useful for a range of therapeutic treatments including joint and soft tissue repair, regulation of skin condition, and for use in organ preservation, such as for use in organ transplant procedures. Advantages of the compositions include that they can be reproducibly produced, without the inherent variability of amniotic fluid from individual donors, and that they are free of fetal waste.

Compositions are provided that contain biologically active components of amniotic fluid including growth factors and other proteins, carbohydrates, lipids, and metabolites. The compositions containing biologically active components of amniotic fluid can be useful for a range of therapeutic treatments including joint and soft tissue repair, regulation of skin condition, and for use in organ preservation, such as for use in organ transplant procedures. Advantages of the compositions include that they can be reproducibly produced, without the inherent variability of amniotic fluid from individual donors, and that they are free of fetal waste.